BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 15509511)

  • 1. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
    Saito Y; Sunamura M; Motoi F; Abe H; Egawa S; Duda DG; Hoshida T; Fukuyama S; Hamada H; Matsuno S
    Cancer Gene Ther; 2006 Mar; 13(3):242-52. PubMed ID: 16179928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
    Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
    Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
    Ai Zheng; 2004 Jul; 23(7):788-93. PubMed ID: 15248913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J; Cho JY; Kim JH; Jung KC; Yun CO
    Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.
    Pipiya T; Sauthoff H; Huang YQ; Chang B; Cheng J; Heitner S; Chen S; Rom WN; Hay JG
    Gene Ther; 2005 Jun; 12(11):911-7. PubMed ID: 15690061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter].
    Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):240-3. PubMed ID: 15144614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
    Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.